Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

Executive Summary

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

You may also be interested in...



FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch

Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study.

Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback

US FDA recommends company start a new study of oral Fabry disease drug, to be designed using the agency's irritable bowel syndrome guidance for measuring efficacy in diarrhea.

Amicus Eyes Breakthrough Drug, PRV Revenue In Scioderm Buy

Amicus Therapeutics chairman and CEO John Crowley had special insight into the value of Scioderm's topical drug candidate Zorblisa (SD-101) – he's been a member of the small, private company's board of directors for two years and became convinced that Amicus could add value to the "breakthrough" treatment for epidermolysis bullosa (EB).

Topics

Related Companies

UsernamePublicRestriction

Register

SC099484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel